Hydromorphone chemical structure
Find information on thousands of medical conditions and prescription drugs.

Hydromorphone

more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
Habitrol
Halcion
Haldol
Haloperidol
Halothane
Heparin sodium
Hepsera
Herceptin
Heroin
Hetacillin
Hexachlorophene
Hexal Diclac
Hexal Ranitic
Hexetidine
Hibiclens
Histidine
Hivid
HMS
Hyalgan
Hyaluronidase
Hycodan
Hycomine
Hydralazine
Hydrochlorothiazide
Hydrocodone
Hydrocortisone
Hydromorphone
Hydromox
Hydroxycarbamide
Hydroxychloroquine
Hydroxystilbamidine
Hydroxyzine
Hyoscine
Hypaque
Hytrin
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Overview

Hydromorphone is a drug used to relieve moderate to severe pain. Hydromorphone is known by the trade names Dilaudid® and Palladone®. It belongs to a category of drugs known as opioid agonists. It is commonly given to patients who have recently undergone surgery or who have suffered serious injury, and it is given intravenously, intramuscularly, rectally, or orally. Hydromorphone is often sought after by opiate drug abusers as it is one of the most potent of all prescription narcotics.

Details

Hydromorphone, a semi-synthetic μ-opioid agonist, is a hydrogenated ketone of morphine and shares the pharmacologic properties typical of opioid analgesics. Hydromorphone and related opioids produce their major effects on the central nervous system and gastrointestinal tract. These include analgesia, drowsiness, mental clouding, changes in mood, euphoria or dysphoria, respiratory depression, cough suppression, decreased gastrointestinal motility, nausea, vomiting, increased cerebrospinal fluid pressure, increased biliary pressure, pinpoint constriction of the pupils, increased parasympathetic activity and transient hyperglycemia. When injected, particularily intravenously, hydromorphone produces more intense contraction sensation in the muscles and a more powerful 'rush' than other opioids, even more so than heroin (diacetylmorphine).

CNS depressants, such as other opioids, anesthetics, sedatives, hypnotics, barbiturates, phenothiazines, chloral hydrate and glutethimide may enhance the depressant effects of hydromorphone. MAO inhibitors (including procarbazine), first-generation antihistamines (brompheniramine, promethazine, diphenhydramine, chlorpheniramine), beta-blockers and alcohol may also enhance the depressant effect of hydromorphone. When combined therapy is contemplated, the dose of one or both agents should be reduced.

Side Effects

Adverse effects of hydromorphone are similar to those of other opioid analgesics, and represent an extension of pharmacological effects of the drug class. The major hazards of hydromorphone include respiratory and CNS depression. To a lesser degree, circulatory depression, respiratory arrest, shock and cardiac arrest have occurred. The most frequently observed adverse effects are sedation, nausea, vomiting, constipation, lightheadedness, dizziness and sweating.

Read more at Wikipedia.org


[List your site here Free!]


The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations
From CHEST, 10/1/05 by Michael Levine

Background: The use of both heroin and cocaine has been associated with asthma exacerbations. However, the magnitude of this effect has not been adequately described. The purpose of this study was to examine the association between cocaine or heroin use and asthma severity.

Methods: We conducted a retrospective chart review of adult patients who had been admitted to an inner-city hospital and who subsequently had received a hospital discharge diagnosis of acute asthma exacerbation. Patients were classified as cocaine users if they had admired to using cocaine within 24 h of symptom onset, or if a positive drug screen result was obtained. A similar classification was employed for heroin. The severity of asthma exacerbations among cocaine and heroin users was compared to severity among nonusers (ie, individuals without evidence of having used either drug within the 24 h preceding symptom onset).

Results: One hundred sixty-six unique patient encounters were identified, and 152 patient records were analyzed. Of these, 27.6% (42 of 152 patients) used cocaine with or without heroin and were classified as cocaine users, while 30.9% (47 of 152 patients) used heroin with or without cocaine and were classified as heroin users. Cocaine users had longer mean lengths of hospital stay than nonusers (3.4 days vs 2.5 days; p < 0.049). Intubation and ICU admission were more common among cocaine users than nonusers (21.4% vs 2.3%, respectively [p = 0.0006]; 31.0% vs 11.5%, respectively [p = 0.0068]). Heroin users were also intubated more frequently than nonusers (17.0% vs 2.3%, respectively; p = 0.0036). Neither the length of hospital stay nor the percentage of ICU admissions was significantly different between heroin users and nonusers.

Conclusion: Heroin and cocaine use are common among adult asthmatic patients admitted to an inner-city hospital. Both cocaine and heroin are significantly associated with the need for intubation. Based on these findings, it may be prudent to screen adults with asthma presenting to an urban emergency department for cocaine and heroin use.

Key words: asthma; cocaine; drug abuse; heroin; intubation; status asthmaticus

Abbreviations: AMA = against medical advice; CI = confidence interval; OR = odds ratio

**********

Asthma is a chronic, inflammatory disease, primarily involving the lower airways. It has been estimated that 14 to 15 million Americans currently have asthma, (1) and the prevalence is increasing. While individuals of all ages and races are affected, children and African Americans have some of the highest hospitalization rates for acute asthma exacerbations. (2,3) In addition, some Hispanic individuals and individuals of lower socioeconomic status have a higher prevalence and severity of asthma. (4) Leikauf and colleagues (5) cite environmental factors as one of the causes for the increasing prevalence of asthma. Some specific reasons cited for the increasing prevalence of asthma in lower socioeconomic regions include poor access to health care, crowded living conditions, and the use of illicit drugs. (6)

Substance abuse, a common problem in many inner-city environments, has substantial social, economic, and medical ramifications. Cocaine was first temporally associated with the development of an acute asthma exacerbation in 1932. (7) Since that time, numerous other reports (8-25) have associated both cocaine and heroin use with asthma exacerbations. Other pulmonary complications of cocaine use have been described elsewhere. (8,9,23)

While cocaine and heroin use have been associated with asthma exacerbations, the magnitude of this effect has not clearly been established. Therefore, we conducted this study in order to quantify the magnitude of this association. Specifically, we assessed whether patients who had been admitted to the hospital for an asthma exacerbation who used these drugs experienced more severe exacerbations than patients not using these drugs.

MATERIALS AND METHODS

This study was conducted at an inner-city, university-affiliated teaching hospital in Chicago. We conducted a retrospective medical record review of all adult patients (age [greater than or equal to] 16 years) who had been admitted to the hospital during the calendar year of 2003 and who ultimately received a hospital discharge diagnosis of acute asthma exacerbation. If a person had multiple hospital admissions for asthma exacerbations during the calendar year, only the first hospitalization was included in the analysis.

Study Subjects

Patients were classified as cocaine users if they either had admitted to using cocaine within the 24 h preceding the onset of dyspnea or if they had a urine drug screen finding that was positive for cocaine metabolites. A similar classification was used for heroin. The comparison group (nonusers) consisted of individuals with no evidence of having used either drug within the 24 h preceding the onset of dyspnea. Patients with a positive urine drug screen finding, who reported using cocaine or heroin within the week but > 24 h before the onset of dyspnea, were also classified as nonusers. Patients were excluded from analysis if there was no documentation of drug use or a urine drug screen had not been performed.

Data Collection

Data abstracted from medical records included patient age, sex, date of visit, smoking history, history of prior intubations, initial vital signs in the emergency department, and disposition from the emergency department (ie, admission to a hospital floor vs ICU admission). In addition, information was collected pertaining to the use of cocaine or heroin (by patient admission), the results of a urine drug screen (if performed), intubation during the hospitalization, and length of time receiving ventilation for those patients who had been intubated. Last, information on length of stay, including the number of days spent in the ICU and the total number of days spent in the hospital were obtained.

The data were collected on a preprinted data abstraction form and then were entered into a standard spreadsheet (Excel 2000, version 9.0.2720; Microsoft; Redmond, WA) by one author (M.L.). Following data entry, the data were independently checked for accuracy by another investigator (M.E.I.).

The urine drug screen for both cocaine and heroin is performed via a homogenous immunoassay method. The urine drug screen for cocaine detects the primary inactive metabolite of cocaine, benzoylecgonine, rather than the cocaine itself. A cutoff of 300 ng/mL is considered to be a positive result for a cocaine metabolite assay by our hospital laboratory. The detection of benzoylecgonine in concentrations of > 300 ng/mL generally implies use within 1 to 2 days. (10) For opiates, the urine drug screen detects morphine and 6-acetylmorphine in the urine; a positive result indicates exposure to morphine, diacetylmorphine (heroin), codeine, hydromorphone, levorphanol, meperidine, or oxycodone/morphine. A cutoff of 2,000 ng/mL is considered to be a positive result by our hospital laboratory. Using the cutoff value of 2,000 ng/mL, a positive result generally indicates use within the previous 12 h. (26)

The need for mechanical ventilation or ICU admission, along with the total length of stay were used as markers for asthma severity. Patients who left the hospital against medical advice (AMA) were included in all data analyses except for length of stay.

Data Analysis

Independent associations were assessed via [chi square] test and Fisher Exact Test (as appropriate) for categoric variables, and t tests were used for assessing continuous variables. Logistic regression analysis was utilized to identify variables that were independently associated with endotracheal intubation and ICU admission. Logistic regression models were also used to obtain odds ratios (ORs) and 95% confidence intervals (CIs) for the association between risk factors (cocaine or heroin) and outcome variables (endotracheal intubation and ICU admission), after adjustment for identified confounders. All statistical analyses were performed using a statistical software package (SAS, version 8.2; SAS Institute; Cary, NC). The study received approval from the institutional review board.

RESULTS

Between January 1, 2003, and December 31, 2003, a total of 166 unique patient encounters were identified. Of the 166 patients, 3 were excluded because neither had a urine drug screen been performed nor was there any documentation of drug use in the chart. Of the remaining 163 charts, 152 (93.3%) were located and included in the study analysis,

Eighteen patients (11.8%) had exclusively used cocaine, and 23 patients (15.1%) had exclusively used heroin. An additional 24 patients (15.8%) had used both cocaine and heroin. Thus, a total of 42 patients (27.6%) used cocaine, and 47 patients (30.9%) used heroin. The overall prevalence of either illicit drug in our study population was 42.8% (65 of 152 patients).

More than half of all subjects were women (62.5%), and the mean age of subjects was 43.2 years. African-Americans accounted for 88.1% of the sample, with the remainder being Hispanic (11.3%) or white (0.7%). Fifty-four percent of the patients were current tobacco smokers, and 33.6% of the patients had been intubated at least once in the past. The characteristics of cocaine users compared to nonusers are presented in Table 1, and the characteristics of heroin users compared to nonusers are presented in Table 2.

Cocaine users were more likely to be tobacco smokers than were nonusers (69.2% vs 41.9%, respectively; p = 0.0046) [Table 1]. Similarly, heroin users were more likely to be tobacco smokers than were non-drug users (75.0% vs 41.9%, respectively; p = 0.0003) [Table 2].

Patients who used either cocaine or heroin were significantly more likely to be intubated during the hospitalization than were those who used neither drug. Among cocaine users, 21.4% were intubated compared to only 2.3% of non-drug users (p = 0.0006) [Table 1]. In the heroin group, similar results were obtained (17% vs 2.3%, respectively; p = 0.0036) [Table 2]. Even after adjusting for tobacco smoking, patients who used cocaine were still more likely to be intubated than those who had not used either cocaine or heroin (adjusted OR, 15.3; 95% CI, 2.7 to 86.7). A similar phenomenon was observed in the heroin group (adjusted OR, 16.5; 95% CI, 2.8 to 97.2).

Patients who used cocaine were more likely to be admitted to the ICU than those who had not used drugs (31.0% vs 11.5%, respectively; p = 0.0068) [Table 1]. Even after adjusting for tobacco smoking, patients who used cocaine were more likely to be admitted to the ICU (adjusted OR, 4.7; 95% CI, 1,6 to 13.8). When comparing the patients who used heroin to those who had not used drugs, there was no statistical difference with regard to ICU admission (Table 2).

Among cocaine users, 14% (9 of 42 patients) left the hospital AMA compared to 25% of heroin users (12 of 47 patients). Only 3% of patients (3 of 87 patients) who had used neither drug left the hospital AMA. Patients leaving the hospital AMA were not included in the analysis of length of stay.

Patients who used cocaine had significantly longer total mean ([+ or -] SD) lengths of stay in the hospital than did the non-drug users (3.4 [+ or -] 2.3 days vs 2.5 [+ or -] 1.8 days, respectively; p = 0.049) [Table 1]. Among patients who had been admitted to the ICU, cocaine users received an average of 4.2 [+ or -] 2.2 days of critical care compared to 1.8 [+ or -] 1.5 days among non-drug users (p = 0.0268) [Table 1]. There was no statistical difference noted when comparing the total length of hospital stay for heroin users compared to non-drug users. However, heroin users admitted to the ICU did spend significantly more days in the ICU than did non-drug users (3.9 days vs 1.8 days, respectively; p = 0.0420) [Table 2].

DISCUSSION

Our results found a 42.8% prevalence of cocaine or heroin use among adult patients who had been admitted for acute asthma exacerbations to an inner-city Chicago hospital. We also found that both cocaine and heroin use were associated with higher intubation rates. Cocaine use, but not heroin use, was also associated with longer lengths of stay and a higher likelihood of being admitted to the ICU. To our knowledge, this study is the first to place numerical values on the extent to which both cocaine and heroin affect acute asthma exacerbations.

We used the length of stay as well as the need for ICU admission or intubation as markers for asthma severity. We chose these parameters because they are readily quantifiable, and subject to little interobserver variability.

In our hospital, patients < 16 years of age are admitted to the pediatric service, while patients [greater than or equal to] 16 years of age are admitted to the medicine service. However, neither asthma nor illicit drug use is uncommon among teenagers. Nonetheless, in order to further minimize the confounding variables, we opted to include only those patients who were [greater than or equal to] 16 years of age, in order to ensure that the same group of physicians had been responsible for the care of all patients in the study.

Pathophysiologically, there are several reasons why both cocaine and heroin might induce an acute asthma exacerbation. Direct thermal injury can occur following the inhalation of either cocaine or heroin. The bronchoconstrictive effects of morphine, which is a metabolite of heroin, have been known since the early 1900s. (27) It is now known that bronchoconstriction after heroin use is likely because of the ability of heroin to directly cause the degranulation of the mast cells, with the subsequent release of preformed inflammatory mediators such as histamines. (28) Furthermore, under normal circumstances, asthmatic patients will increase their respiratory rate in an effort to compensate for the relative hypoxemia caused by bronchoconstriction. Since opioids cause respiratory depression, it is possible that the heroin-induced respiratory depression at least partly thwarts the ability of the body to adequately compensate, thus exacerbating the severity of an asthma attack.

Heroin users were clearly intubated more frequently than patients who had used neither cocaine nor heroin. However, unlike cocaine users, heroin users did not have any longer lengths of hospital stay or more days spent receiving mechanical ventilation when compared to non-drug users. Thus, it is certainly possible that heroin induced some degree of respiratory depression, and this respiratory depression contributed to a worsening initial presentation. Nonetheless, all patients were thought to be experiencing an asthma exacerbation, and not simply respiratory depression, by at least two board-certified attending physicians (ie, an emergency medicine physician, who saw the patient in the emergency department, and an internist or pulmonary/critical care specialist, who treated the patient once they had been admitted to the hospital). Regardless of the etiology, the use of heroin was associated with a more severe acute asthma exacerbation than was observed in non-drug users. This initial presentation has significant implications for the early management and disposition of heroin-using patients experiencing an acute asthma exacerbation.

Cocaine and its adulterants can cause inflammation of the respiratory epithelium. (6,9) It is most likely that inhaled cocaine serves as a topical irritant on the airways. (9) In addition, some cases of cocaine-induced asthma exacerbations may occur through an IgE-mediated sensitivity. (15)

There have been several case reports (8,20) of life-threatening or fatal status asthmaticus following heroin insufflation in the same geographic region as ours. Krantz and colleagues (20) examined the prevalence of drug use in asthmatic patients who had been admitted to the ICU and compared the pattern of drug use in these patients to patients in the ICU who had been admitted for diabetic ketoacidosis. The authors observed that asthmatic patients in the ICU were more likely to have used heroin than were the diabetic ketoacidosis patients in the ICU. They did not observe any difference between the two groups regarding cocaine use. The reasons for the discrepancies observed in our study compared with the study by Krantz and colleagues (20) are not entirely clear. It is possible, however, that the small number of patients who used only cocaine in their study merely did not permit Krantz and colleagues (20) to appreciate the effect of cocaine.

In our study, there were no fatalities. Levenson and colleagues (13) examined asthma deaths in Cook County, IL, where our hospital is located. They reported that 31.5% of asthma deaths were confounded by substance abuse or alcohol ingestion. Cocaine was the most frequently identified drug found on toxicologic analysis in their study. Weitzman and colleagues (29) examined asthma deaths in the state of Maryland. They reported that 17.5% of asthma patients who died had a history of drug abuse, and that 12.7% of them had toxicology screens that were positive for drugs that are normally abused. While our study revealed a much higher rate of drug use, the study by Weitzman and colleagues (29) included young children. Therefore, it is likely that among adults, the percentage of patients with toxicologic screens that were positive for drugs of abuse would be higher. The study by Weitzman et al (29) also demonstrated that the majority of fatal asthma attacks are likely to begin at home. Thus, it is possible that many patients who die from an acute asthma exacerbation would do so either prior to arriving in the emergency department or while in the emergency department. Therefore, they would not have been admitted to the hospital. If this scenario is correct, we might have missed patients with the most severe cases of asthma, as we included only those patients who had been admitted to the hospital.

Given the high prevalence rate of both cocaine and heroin use in our population, it is unlikely that patient underreporting of their drug usage contributed significantly to our findings. However, even if underreporting were to occur, one would expect our observed differences to be even larger. Thus, if any drug-using patients were incorrectly categorized into a nonuser group rather than a user group, we would expect the true differences between the two groups to be even greater.

Our study was limited by its retrospective nature. As a result, we were limited to the data that were recorded in the medical chart, and our conclusions are limited by the quality and completeness of those data. Gilbert and colleagues (30) have noted that retrospective reviews can further be limited by the specific variables that are chosen for examination. For example, parameters such as medication histories, ECG results, or "appropriateness of care" are subject to much interrater variability during retrospective reviews. (30) However, in our study, most of the data abstracted included continuous variables (ie, days in the hospital) and dichotomous variables (ie, intubated or not). This fact likely reduced any bias on behalf of the abstracter and, thus, reduced some of the limitations of a retrospective study.

The routes of drug consumption were too inconsistently documented to permit any meaningful analysis. In our experience, however, most of our patients smoke these drugs, rather than inject or insufflate them. It is likely that drug-induced asthma will primarily be observed in patients who smoke the drug, as this route is associated with the most direct damage and inflammation of the bronchial epithelium. (15) Support for this theory has come from a study by Tashkin and colleagues, (31) who examined airway dynamics in patients who consumed cocaine via various routes. They observed that smoking cocaine, but not injecting cocaine, produced acute bronchoconstriction. However, it should be noted that the insufflation of cocaine has also been linked to near-fatal status asthmaticus. (18)

Another limitation of the study is that the limited sample size made it difficult to distinguish between individuals who had used one drug vs both drugs in the analysis. In other words, when assessing the association between cocaine use and the severity of asthma exacerbations, cocaine users, whether they had used only cocaine or both cocaine and heroin, were compared to non-drug users. Similarly, when assessing the relationship with heroin use, heroin users, whether they had used only heroin or both heroin and cocaine, were compared to non-drug users. It would have been ideal to have examined individuals who had used only cocaine (n = 18), individuals who had used only heroin (n = 23), and individuals who had used both (n = 24) separately, but the small numbers of patients would have made the adjusted logistic regression models unstable. It could, however, be argued that this detail is irrelevant. For example, if a clinician knows that a patient has used cocaine, then the clinician knows that the patient is at risk for a more severe exacerbation, regardless of whether or not other drugs were consumed simultaneously.

We only examined cocaine and heroin. While we did correct for tobacco smoking, we neither investigated nor corrected the data for other potentially confounding variables such as exposure to marijuana smoke or second-hand tobacco smoke, as well as for the concurrent use of alcohol. Other potential confounding variables such as a history of allergies, current medications being used, and access to medical care were also not measured. The consideration of marijuana might have been important, as marijuana smoking has several pulmonary effects. While marijuana is associated with increased airway injury and hyperresponsivenessy, (32,33) it is also associated with bronchodilation. (34) The combination of cocaine and ethanol produces the metabolite cocaethylene, which is believed to be more toxic to the brain and heart than either parent compound alone. (35) It is not known whether cocaethylene produces specific pulmonary complications beyond that produced by cocaine alone.

The high prevalence of both tobacco use and drug use in our population may reduce the generalizability of our study to regions where drug use is less prevalent. While there is clearly an association between cocaine use and asthma, and possibly between heroin use and asthma, the limited sample size makes it difficult for us to conclude anything about the strength of the association. Also, our study design does not permit us to evaluate a dose-response relationship. A prospective study is needed to evaluate whether the route of administration affects the degree of bronchoconstriction. In addition, a prospective study would allow us to further correct for some additional confounding variables.

It is interesting to note that there is a higher prevalence of male patients in the drug-abusing groups. This finding likely reflects the overall patterns of drug abuse, as men use drugs more frequently than women. (36) In addition, patients who used these illicit drugs left the hospital AMA much more frequently than did patients who did not use drugs. The exact reasons are not entirely clear, but could be further investigated in a prospective study. In addition, this observation would imply that clinicians should commence patient education early in the course of a hospital stay.

CONCLUSION

We have reported a surprisingly high prevalence of cocaine and heroin use among adults who were admitted to an inner-city hospital for asthma exacerbation. The use of cocaine is a risk factor for triggering severe acute asthma exacerbations. Heroin also appears to be a risk factor for intubation. It is probable that the high prevalence of drug use in inner-city populations contributes to the high rates of asthma exacerbations in patients in inner-city settings. Patients who have been admitted to the hospital with acute asthma exacerbations in areas where illicit drug use is prevalent should be screened for the use of cocaine or heroin.

Manuscript received August 10, 2004; revision accepted February 28, 2005.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal. org/misc/reprints.shtml).

REFERENCES

(1) Mannino DM, Homa DM, Akinbami LF, et al. Surveillance for asthma: United States, 1980-1999. MMWR Surveill Summ 2002; 51:1-13

(2) National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997; NIH Publication No. 97-4051

(3) Thomas SD, Whitman S. Asthma hospitalizations and mortality in Chicago: an epidemiologic overview. Chest 1999; 116:135S-141S

(4) Coultas DB, Gong HJR, Grand R, et al. Respiratory diseases in minorities of the United States. Am J Respir Crit Care Med 1994; 149(suppl):S93-S131

(5) Leikauf GD, Kline S, Albert RE, et al. Evaluation of a possible association of urban air toxics and asthma. Environ Health Perspect 1995; 103:253-271

(6) Rome LA, Lippmann ML, Dalsey WC, et al. Prevalence of cocaine use and its impact on asthma exacerbations in an urban population. Chest 2000; 117:1324-1329

(7) Waldbott GL. Asthma due to a local anesthetic. JAMA 1932; 99:1942

(8) Cygan J, Trunsky M, Corbridge T. Inhaled heroin-induced status asthmaticus: five cases and a review of the literature. Chest 2000; 117:272-275

(9) Haim DY, Lippmann ML, Goldberg SK, et al. The pulmonary complications of crack cocaine: a comprehensive review. Chest 1995; 107:233-240

(10) Warner EA. Cocaine abuse. Ann Intern Med 1993; 119:226-235

(11) Rubin RB, Neugarten J. Cocaine-associated asthma. Am J Med 1990; 88:438-439

(12) Panacek CA, Jouriles NJ, Singer A, et al. Is unexplained bronchospasm associated with use of cocaine [abstract]? Ann Emerg Med 1991; 20(suppl):488-489

(13) Levenson T, Greenberger PA, Donoghue ER, et al. Asthma deaths confounded by substance abuse. Chest 1996; 110:604-610

(14) Perper JA, Van Thiel DH. Respiratory complications of cocaine abuse. Recent Dev Alcohol 1992; 10:363-377

(15) Rebhun J. Association of asthma and freebase smoking. Ann Allergy 1988; 60:339-341

(16) Ettinger NA. A review of the respiratory effects of smoking cocaine. Am J Med 1989; 87:664-668

(17) Rao AN, Polos PG, Walther FA. Crack abuse and asthma: a fatal combination. N Y State J Med 1990; 90:511-512

(18) Averbach M, Casey KK, Frank E. Near-fatal status asthmaticus induced by nasal insufflation of cocaine. South Med J 1996; 89:340-341

(19) Gaeta TJ, Hammock R, Spevack TA, et al. Association between substance abuse and acute exacerbation of bronchial asthma. Acad Emerg Med 1996; 3:1170-1171

(20) Krantz AJ, Hershow RC, Prachand N, et al. Heroin insufflation as a trigger for patients with life-threatening asthma. Chest 2003; 123:510-517

(21) Osborn HH, Tang M, Bradley K, et al. New-onset bronchospasm or recrudescence of asthma associated with cocaine abuse. Acad Emerg Med 1997; 4:689-692

(22) Hughes S, Calverley PMA. Heroin inhalation and asthma. BMJ 1997; 297:1151-1152

(23) Albertson TE, Walby WF, Derlet RW. Stimulant-induced pulmonary toxicity. Chest 1995; 108:1140-1149

(24) de los Bueis AB, Vega AP, Ramos JLS, et al. Bronchial hyperreactivity in patients who inhale heroin mixed with cocaine vaporized on aluminum foil. Chest 2002; 121:1223-1230

(25) Oliver RM. Bronchospasm and heroin inhalation [letter]. Lancet 1986; 1:915

(26) Cone EJ, Jufer R, Darwin WD, et al. Forensic drug testing for opiates: VII. Urinary excretion profile for intranasal (snorted) heroin. J Anal Toxicol 1995; 20:379-392

(27) Dixon WE, Brodie TB. Contributions to the physiology of the lungs: Part 1. The bronchial muscles, their innervation, and the action of the drugs upon them. J Physiol 1903; 29:171

(28) Withington DE, Patrick JA, Reynolds F. Histamine release by morphine and diamorphine in man. Anaesthesia 1993; 48: 26-29

(29) Weitzman JB, Kanarek NF, Smialek JE. Medical examiner asthma death autopsies: a distinct subgroup of asthma deaths with implications for public health preventative strategies. Arch Pathol Lab Med 1998; 122:691-699

(30) Gilbert EH, Lowenstein SR, Koziol-McLain J, et al. Chart reviews in emergency medicine research: what are the methods? Ann Emerg Med 1996; 27:305-308

(31) Tashkin DP, Kleerup EC, Koyal SN, et al. Acute effects of inhaled and IV cocaine on airway dynamics. Chest 1996; 110:904-910

(32) Tashkin DP, Simmons MS, Chang P, et al. Effects of smoked substance abuse on nonspecific airway hyperresponsiveness. Am Rev Respir Dis 1993; 147:97-103

(33) Tashkin DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Opin Puhn Med 2001; 7:43-61

(34) Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42:327-360

(35) Rose JS. Cocaethylene: a current understanding of the active metabolite of cocaine and ethanol. Am J Emerg Med 1994; 12:489-490

(36) US Department of Health and Human Services. Health, United States, 2004: with Chartbook on Trends in the Health of Americans. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Health Statistics, September 2004; Department of Health and Human Services Publication No. 2004-1232

Michael Levine, Md; Maria Elena Iliescu, MD; Helen Margellos-Anast, MPH; Melanie Estarziau, MPH; and David A. Ansell, MD, MPH

* From the Harvard-Affiliated Emergency Medicine Residency Program (Dr. Levine), Brigham and Women's and Massachusetts General Hospital, Boston, MA; the Rosalind Franklin University of Medicine and Science/The Chicago Medical School, Chicago, IL; and the Department of Medicine (Drs. Iliescu and Ansell) and the Sinai Urban Health Institute (Ms. Margellos-Anast and Ms. Estarziau), Mount Sinai Hospital, Chicago, IL.

Correspondence to: Michael Levine, MD, Harvard Affiliated Emergency Medicine Residency, Brigham and Women's Hospital, 75 Francis St, Neville House, second floor, Boston, MA 02115; e-mail: mdlevine@partners.org

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Hydromorphone
Home Contact Resources Exchange Links ebay